Profile of nintedanib in the treatment of solid tumors: The evidence to date

Niranjan Awasthi, Roderich E. Schwarz

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approved for cancer therapy. Novel antiangiogenic agents, such as sunitinib, sorafenib, pazopanib, or vandetanib that target additional proangiogenic signaling pathways beyond VEGF, have also been approved for the treatment of various malignant diseases. While most of these agents are approved in combination with cytotoxic chemotherapy for indications including metastatic colorectal cancer, non-small-cell lung cancer, breast cancer, renal cell carcinoma (RCC), and gastric cancer, some are used as approved monotherapy for advanced RCC, hepatocellular carcinoma and medullary thyroid cancer. Major challenges to the success of antiangiogenic therapy include associated toxicity risks, limitation of efficacy through the possible development of resistance and induction or promotion of metastatic progression. Nintedanib (formally known as BIBF 1120) is a triple angiokinase inhibitor of VEGF, fibroblast growth factor, platelet-derived growth factor signaling with lesser activity against RET, Flt-3, and Src. Through this unique targeting profile nintedanib has demonstrated significant antitumor activity in several tumor types in preclinical studies. Nintedanib has also shown promising clinical efficacy in combination with docetaxel and has been approved for treating patients with locally advanced and metastatic non-small-cell lung cancer in Europe. Nintedanib has also been found to be clinically promising in terms of efficacy and safety in several other solid tumors including ovarian cancer (Phase III), RCC (Phase II), and prostate cancer (Phase II). This review article provides a comprehensive summary of the preclinical and clinical efficacy of nintedanib in the treatment of solid tumors.

Original languageEnglish (US)
Pages (from-to)3691-3701
Number of pages11
JournalOncoTargets and Therapy
Volume8
DOIs
StatePublished - Dec 8 2015

Fingerprint

Renal Cell Carcinoma
Neoplasms
Vascular Endothelial Growth Factor A
Angiogenesis Inhibitors
docetaxel
Non-Small Cell Lung Carcinoma
Therapeutics
Breast Neoplasms
Fibroblast Growth Factors
Platelet-Derived Growth Factor
nintedanib
Ovarian Neoplasms
Stomach Neoplasms
Hepatocellular Carcinoma
Colorectal Neoplasms
Prostatic Neoplasms
Monoclonal Antibodies
Neoplasm Metastasis
Safety
Drug Therapy

Keywords

  • Angiogenesis
  • BIBF 1120
  • Nintedanib
  • Tyrosine kinase inhibitors
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Profile of nintedanib in the treatment of solid tumors : The evidence to date. / Awasthi, Niranjan; Schwarz, Roderich E.

In: OncoTargets and Therapy, Vol. 8, 08.12.2015, p. 3691-3701.

Research output: Contribution to journalArticle

Awasthi, Niranjan ; Schwarz, Roderich E. / Profile of nintedanib in the treatment of solid tumors : The evidence to date. In: OncoTargets and Therapy. 2015 ; Vol. 8. pp. 3691-3701.
@article{b101ace400a34f95abdc9dcfde036486,
title = "Profile of nintedanib in the treatment of solid tumors: The evidence to date",
abstract = "Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approved for cancer therapy. Novel antiangiogenic agents, such as sunitinib, sorafenib, pazopanib, or vandetanib that target additional proangiogenic signaling pathways beyond VEGF, have also been approved for the treatment of various malignant diseases. While most of these agents are approved in combination with cytotoxic chemotherapy for indications including metastatic colorectal cancer, non-small-cell lung cancer, breast cancer, renal cell carcinoma (RCC), and gastric cancer, some are used as approved monotherapy for advanced RCC, hepatocellular carcinoma and medullary thyroid cancer. Major challenges to the success of antiangiogenic therapy include associated toxicity risks, limitation of efficacy through the possible development of resistance and induction or promotion of metastatic progression. Nintedanib (formally known as BIBF 1120) is a triple angiokinase inhibitor of VEGF, fibroblast growth factor, platelet-derived growth factor signaling with lesser activity against RET, Flt-3, and Src. Through this unique targeting profile nintedanib has demonstrated significant antitumor activity in several tumor types in preclinical studies. Nintedanib has also shown promising clinical efficacy in combination with docetaxel and has been approved for treating patients with locally advanced and metastatic non-small-cell lung cancer in Europe. Nintedanib has also been found to be clinically promising in terms of efficacy and safety in several other solid tumors including ovarian cancer (Phase III), RCC (Phase II), and prostate cancer (Phase II). This review article provides a comprehensive summary of the preclinical and clinical efficacy of nintedanib in the treatment of solid tumors.",
keywords = "Angiogenesis, BIBF 1120, Nintedanib, Tyrosine kinase inhibitors, VEGF",
author = "Niranjan Awasthi and Schwarz, {Roderich E.}",
year = "2015",
month = "12",
day = "8",
doi = "10.2147/OTT.S78805",
language = "English (US)",
volume = "8",
pages = "3691--3701",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Profile of nintedanib in the treatment of solid tumors

T2 - The evidence to date

AU - Awasthi, Niranjan

AU - Schwarz, Roderich E.

PY - 2015/12/8

Y1 - 2015/12/8

N2 - Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approved for cancer therapy. Novel antiangiogenic agents, such as sunitinib, sorafenib, pazopanib, or vandetanib that target additional proangiogenic signaling pathways beyond VEGF, have also been approved for the treatment of various malignant diseases. While most of these agents are approved in combination with cytotoxic chemotherapy for indications including metastatic colorectal cancer, non-small-cell lung cancer, breast cancer, renal cell carcinoma (RCC), and gastric cancer, some are used as approved monotherapy for advanced RCC, hepatocellular carcinoma and medullary thyroid cancer. Major challenges to the success of antiangiogenic therapy include associated toxicity risks, limitation of efficacy through the possible development of resistance and induction or promotion of metastatic progression. Nintedanib (formally known as BIBF 1120) is a triple angiokinase inhibitor of VEGF, fibroblast growth factor, platelet-derived growth factor signaling with lesser activity against RET, Flt-3, and Src. Through this unique targeting profile nintedanib has demonstrated significant antitumor activity in several tumor types in preclinical studies. Nintedanib has also shown promising clinical efficacy in combination with docetaxel and has been approved for treating patients with locally advanced and metastatic non-small-cell lung cancer in Europe. Nintedanib has also been found to be clinically promising in terms of efficacy and safety in several other solid tumors including ovarian cancer (Phase III), RCC (Phase II), and prostate cancer (Phase II). This review article provides a comprehensive summary of the preclinical and clinical efficacy of nintedanib in the treatment of solid tumors.

AB - Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approved for cancer therapy. Novel antiangiogenic agents, such as sunitinib, sorafenib, pazopanib, or vandetanib that target additional proangiogenic signaling pathways beyond VEGF, have also been approved for the treatment of various malignant diseases. While most of these agents are approved in combination with cytotoxic chemotherapy for indications including metastatic colorectal cancer, non-small-cell lung cancer, breast cancer, renal cell carcinoma (RCC), and gastric cancer, some are used as approved monotherapy for advanced RCC, hepatocellular carcinoma and medullary thyroid cancer. Major challenges to the success of antiangiogenic therapy include associated toxicity risks, limitation of efficacy through the possible development of resistance and induction or promotion of metastatic progression. Nintedanib (formally known as BIBF 1120) is a triple angiokinase inhibitor of VEGF, fibroblast growth factor, platelet-derived growth factor signaling with lesser activity against RET, Flt-3, and Src. Through this unique targeting profile nintedanib has demonstrated significant antitumor activity in several tumor types in preclinical studies. Nintedanib has also shown promising clinical efficacy in combination with docetaxel and has been approved for treating patients with locally advanced and metastatic non-small-cell lung cancer in Europe. Nintedanib has also been found to be clinically promising in terms of efficacy and safety in several other solid tumors including ovarian cancer (Phase III), RCC (Phase II), and prostate cancer (Phase II). This review article provides a comprehensive summary of the preclinical and clinical efficacy of nintedanib in the treatment of solid tumors.

KW - Angiogenesis

KW - BIBF 1120

KW - Nintedanib

KW - Tyrosine kinase inhibitors

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84949658578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949658578&partnerID=8YFLogxK

U2 - 10.2147/OTT.S78805

DO - 10.2147/OTT.S78805

M3 - Article

C2 - 26677336

AN - SCOPUS:84949658578

VL - 8

SP - 3691

EP - 3701

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -